Cilostazol inhibits cytokine-induced nuclear factor-κB activation via AMP-activated protein kinase activation in vascular endothelial cells

Cardiovascular Research

Volumn 81, Issue 1, 2009, Pages 133-139

  Hattori, Yoshiyuki ^a   Suzuki, Kunihiro ^a   Tomizawa, Atsuko ^a   Hirama, Noriko ^a   Okayasu, Toshie ^a   Hattori, Sachiko ^a   Satoh, Hiroko ^a   Akimoto, Kazumi ^a   Kasai, Kikuo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

AMPK; Cilostazol; Cyclic AMP; Endothelial cells; NF B

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; ACETYL COENZYME A CARBOXYLASE; ADENYLATE CYCLASE INHIBITOR; CILOSTAZOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL GENE; CELL ADHESION; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; MONOCYTE; PHOSPHORYLATION; PRIORITY JOURNAL; RNA INTERFERENCE; THROMBOCYTE AGGREGATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASODILATATION;

ANTIGENS, CD31; CELLS, CULTURED; CHEMOKINE CCL2; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; E-SELECTIN; ENDOTHELIUM, VASCULAR; HUMANS; I-KAPPA B PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; NF-KAPPA B; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASES; RNA, MESSENGER; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 57749183407     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn226     Document Type: Article

References (26)

1. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler 2005;6(Suppl.):3-11.
2. Gotoh F, Tohgi H, Hirai S1, Terashi A, Fukuuchi Y. Cilostazol stroke prevention study: a placebo-controlled doubleblinded trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9: 147-157.
3. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis. The muiticenter double-blind placebo-controlled trial of cilostazol in symptomatic intra-cranial stenosis. Stroke 2005;36:782-786.
4. Dawson HG, Culter BS, Hiatt WR. A comparison of cilostazol and pentoxifylline for intermittent claudication. Am J Med 2000;109:523-530.
5. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB et al. A new pharmacological multicenter trial. Arch Intern Med 1999;159:2041-2050.
6. The PROMISE Study Research Group, Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
7. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87:28D-33D.
8. Ochiai M, Eto K, Takeshita S, Yokoyama N, Oshima A, Kondo K et al. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. Am J Cardiol 1999;84:1074-1076.
9. Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990;57:617-623.
10. Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002;16:539-547.
11. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715-1722.
12. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999;85:199-207.
13. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991;251:788-791.
14. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2 -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897.
15. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255-264.
16. O'Connell KA, Edidin M. A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol 1990;144:521-525.
17. Hattori Y, Suzuki M, Hattori S, Kasai K. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 2002;39:22-28.
18. Kamata H, Manabe T, Oka S, Kamata K, Hirata H. Hydrogen peroxide activates IkappaB kinases through phosphorylation of serine residues in the activation loops. FEBS Lett 2002;519:231-237.
19. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006;116:1776-1783.
20. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-21103.
21. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin Inhibits Cytokine-Induced NF-kB Activation via AMPK Activation in Vascular Endothelial Cells. Hypertension 2006;47:1183-1188.
22. Hardie DG. The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 2004;117:5479-5487.
23. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I. 5-aminoimidazole-4-carboxamide-1- beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci 2004;24:479-487.
24. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique anti-thrombotic agent. Curr Pharm Des 2003;9:2289- 2302.
25. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006;189:350-357.
26. Hurley RL, Barré LK, Wood SD, Anderson KA, Kemp BE, Means AR et al. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 2006;281:36662-36672.